Integrating drug permeability with dissolution profile to develop IVIVC

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 7, 2012, Pages 354-365

  Takano, Ryusuke ^a   Kataoka, Makoto ^b   Yamashita, Shinji ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

dissolution; IVIVC; oral absorption; permeation; solubility

Indexed keywords

CILOSTAZOL; DANAZOL; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG PENETRATION; DRUG QUALITY; DRUG SOLUBILITY; DRUG TRANSPORT; FOOD INTAKE; HUMAN; IN VITRO SELECTION; IN VIVO STUDY; INTESTINE ABSORPTION; MATHEMATICAL ANALYSIS; MAXIMUM PERMISSIBLE DOSE; MEMBRANE PERMEABILITY; MOLECULAR MIMICRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PASSIVE TRANSPORT; QUALITY CONTROL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; MOUTH MUCOSA; NONLINEAR DYNAMICS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84867103706     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1792     Document Type: Article

References (56)

1. Curatolo W,. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. PSTT 1998; 1: 387-393.
2. Johnson KC, Swindell AC,. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 1996; 13: 1795-1798.
3. Sun D, Lennernas H, Welage LS, et al,. Comparison of human duodenum and Caco-2 gene expression profiles for 12000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002; 19: 1400-1416.
4. Dressman JB, Vertzoni M, Goumas K, Reppas C,. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 2007; 59: 591-602.
5. Takano R, Sugano K, Higashida A, et al,. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res 2006; 23: 1144-1156.
6. Yu LX,. An integrated model for determining causes of poor oral drug absorption. Pharm Res 1999; 16: 1883-1887.
7. Dressman JB, Amidon GL, Reppas C, Shah VP,. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-22.
8. Hirtz J,. The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol 1985; 19 (Suppl 2): 77S-83S.
9. Zia H, Chokshi RJ, Sandhu HK, Shah NH, Malick WA,. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons. Drug Deliv 2007; 14: 33-45.
10. Gao P,. Amorphous pharmaceutical solids: characterization, stabilization, and development of marketable formulations of poorly soluble drugs with improved oral absorption. Mol Pharm 2008; 5: 903.
11. Kennedy M, Hu J, Gao P, et al,. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol Pharm 2008; 5: 981-993.
12. Guzman HR, Tawa M, Zhang Z, et al,. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007; 96: 2686-2702.
13. Takano R, Takata N, Saito R, et al,. Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm 2010; 7: 1431-1440.
14. Bak A, Gore A, Yanez E, et al,. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 2008; 97: 3942-3956.
15. Shiraki K, Takata N, Takano R, Hayashi Y, Terada K,. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res 2008; 25: 2581-2592.
16. Lu GW, Hawley M, Smith M, Geiger BM, Pfund W,. Characterization of a novel polymorphic form of celecoxib. J Pharm Sci 2006; 95: 305-317.
17. Ping Gao AA, Alvarez F, Hu J, Li L, Ma C, Surapaneni S,. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci 2009; 98: 516-528.
18. Ozaki S, Minamisono T, Yamashita T, Kato T, Kushida I,. Supersaturation-nucleation behavior of poorly soluble drugs and its impact on the oral absorption of drugs in thermodynamically high-energy forms. J Pharm Sci 2012; 101: 214-222.
19. Dressman JB, Reppas C,. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000; 11 (Suppl 2): S73-S80.
20. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB,. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
21. Naylor LJ, Bakatselou V, Rodriguez-Hornedo N, Weiner ND, Dressman JB,. Dissolution of steroids in bile salt solutions is modified by the presence of lecithin. Eur J Pharm Biopharm 1995; 41: 346-353.
22. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C,. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 1999; 16: 1876-1882.
23. Nicolaides E, Symillides M, Dressman JB, Reppas C,. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001; 18: 380-388.
24. Jantratid E, Janssen N, Reppas C, Dressman JB,. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25: 1663-1676.
25. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C,. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm 2005; 60: 413-417.
26. Yano K, Masaoka Y, Kataoka M, Sakuma S, Yamashita S,. Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes. J Pharm Sci 2010; 99: 1336-1345.
27. Ginski MJ, Polli JE,. Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system. Int J Pharm 1999; 177: 117-125.
28. Kobayashi M, Sada N, Sugawara M, Iseki K, Miyazaki K,. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharm 2001; 221: 87-94.
29. Motz SA, Klimundová J, Schaefer UF, et al,. Automated measurement of permeation and dissolution of propranolol HCl tablets using sequential injection analysis. Anal Chim Acta 2007; 581: 174-180.
30. Shi Y, Gao P, Gong Y, Ping H,. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption. Mol Pharm 2010; 7: 1458-1465.
31. Kataoka M, Masaoka Y, Yamazaki Y, Sakane T, Sezaki H, Yamashita S,. In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs. Pharm Res 2003; 20: 1674-1680.
32. Charman WN, Rogge MC, Boddy AW, Berger BM,. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol 1993; 33: 381-386.
33. Crounse RG,. Effective use of griseofulvin. Arch Dermatol 1963; 87: 176-178.
34. Lange H, Eggers R, Bircher J,. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988; 34: 315-317.
35. Kataoka M, Masaoka Y, Sakuma S, Yamashita S,. Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. J Pharm Sci 2006; 95: 2051-2061.
36. Kataoka M, Itsubata S, Masaoka Y, Sakuma S, Yamashita S,. In vitro dissolution/permeation system to predict the oral absorption of poorly water-soluble drugs: effect of food and dose strength on it. Biol Pharm Bull 2011; 34: 401-407.
37. Jiang W, Kim S, Zhang X, et al,. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm 2011; 418: 151-160.
38. Kovacevic I, Parojcic J, Homsek I, Tubic-Grozdanis M, Langguth P,. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2009; 6: 40-47.
39. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
40. Agoram B, Woltosz WS, Bolger MB,. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl 1): S41-S67.
41. Grassand GM, Sinko PJ,. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54: 433-451.
42. Dokoumetzidis A, Kalantzi L, Fotaki N,. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opin Drug Metab Toxicol 2007; 3: 491-505.
43. Sugano K,. Introduction to computational oral absorption simulation. Expert Opin Drug Metab Toxicol 2009; 5: 259-293.
44. Nernst W,. Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Physikal Chem 1904; 47: 52-55.
45. Dressmanand JB, Fleisher D,. Mixing-tank model for predicting dissolution rate control or oral absorption. J Pharm Sci 1986; 75: 109-116.
46. Hintz RJ, Johnson KC,. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989; 51: 9-17.
47. Sugano K,. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. Int J Pharm 2011; 405: 79-89.
48. Braun RJ, Parrott EL,. Influence of viscosity and solubilization on dissolution rate. J Pharm Sci 1972; 61: 175-178.
49. Crison JR, Shah VP, Skelly JP, Amidon GL,. Drug dissolution into micellar solutions: development of a convective diffusion model and comparison to the film equilibrium model with application to surfactant-facilitated dissolution of carbamazepine. J Pharm Sci 1996; 85: 1005-1011.
50. Okazaki A, Mano T, Sugano K,. Theoretical dissolution model of poly-disperse drug particles in biorelevant media. J Pharm Sci 2007; 97: 1843-1852.
51. Avdeef A,. Absorption and Drug Development. Wiley-Interscience: Hoboken, NJ, 2003.
52. Lennernas H,. Human intestinal permeability. J Pharm Sci 1998; 87: 403-410.
53. Levitt MD, Furne JK, Strocchi A, Anderson BW, Levitt DG,. Physiological measurements of luminal stirring in the dog and human small bowel. J Clin Invest 1990; 86: 1540-1547.
54. Yamashita S, Takashima T, Kataoka M, et al,. PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats. J Nucl Med 2011; 52: 249-256.
55. Sugano K,. Fraction of dose absorbed calculation: comparison between analytical solution based on one compartment steady state approximation and dynamic seven compartment model. Chem-Bio Informatics Journal 2009; 9: 75-93.
56. Takano R, Furumoto K, Shiraki K, et al,. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res 2008; 25: 2334-2344.